Literature DB >> 11076310

Lymphokines in bleomycin-induced lung injury in bleomycin-sensitive C57BL/6 and -resistant BALB/c mice.

I Gur1, R Or, M J Segel, M Shriki, G Izbicki, R Breuer.   

Abstract

To study the pattern of lymphokines in bleomycin-induced lung injury, T cells were isolated from lung interstitial tissue (LIL), peribronchial lymphatic tissue (PBLT), and bronchoalveolar lavage (BAL) fluid of bleomycin-"sensitive" C57Bl/6 and bleomycin-"resistant" BALB/c mice at 3, 6, and 14 days following intratracheal instillation of bleomycin or saline. After 48 hours in culture, conditioned media were collected and assayed with specific enzyme-linked immunosorbent assay (ELISA) for interferon (IFN)-gamma, interleukin (IL)-2, IL-4 and IL-5. In bleomycin-treated C57B1/6 mice, IFN-gamma production was increased up to 20-fold at 3 and 6 days in LIL, and at 3 days in PBLT lymphocytes. IL-4 production was slightly decreased in LIL and PBLT lymphocytes at 14 days. IL-2 and IL-5 were not changed by bleomycin. In BALB/c mice, IFN-gamma production was increased 5-fold at 14 days, and IL-2 production at 6 days, in LIL but not PBLT. IL-4 and IL-5 were not significantly changed. The increase in IFN-gamma may play a role in the pathogenesis of bleomycin-induced lung injury. Differences in the cytokine pattern between the strains of mice may contribute to the variable strain susceptibility in bleomycin-induced lung injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11076310     DOI: 10.1080/019021400750048072

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  7 in total

1.  Angiotensin-converting enzyme (ACE) gene polymorphisms are associated with idiopathic pulmonary fibrosis.

Authors:  Soo-Taek Uh; Tae-Hoon Kim; Eun-Young Shim; An-Soo Jang; Sung-Woo Park; Jong-Sook Park; Byung-Lae Park; Byoung Whui Choi; Hyoung Doo Shin; Dong Soon Kim; Choon-Sik Park
Journal:  Lung       Date:  2013-05-09       Impact factor: 2.584

2.  Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis.

Authors:  Toru Kimura; Yukio Ishii; Keigyou Yoh; Yuko Morishima; Takashi Iizuka; Takumi Kiwamoto; Yosuke Matsuno; Shinsuke Homma; Akihiro Nomura; Tohru Sakamoto; Satoru Takahashi; Kiyohisa Sekizawa
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis.

Authors:  Yasuhito Hamaguchi; Yoriko Nishizawa; Masahide Yasui; Minoru Hasegawa; Yuko Kaburagi; Kazuhiro Komura; Tetsuya Nagaoka; Eriko Saito; Yuka Shimada; Kazuhiko Takehara; Takafumi Kadono; Douglas A Steeber; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  IL-21 Promotes Pulmonary Fibrosis through the Induction of Profibrotic CD8+ T Cells.

Authors:  Tia Y Brodeur; Tara E Robidoux; Jason S Weinstein; Joseph Craft; Susan L Swain; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2015-10-30       Impact factor: 5.422

5.  E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis.

Authors:  Mayuka Horikawa; Manabu Fujimoto; Minoru Hasegawa; Takashi Matsushita; Yasuhito Hamaguchi; Ayako Kawasuji; Yukiyo Matsushita; Tomoyuki Fujita; Fumihide Ogawa; Kazuhiko Takehara; Douglas A Steeber; Shinichi Sato
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

6.  ADAM33 gene polymorphisms are associated with the risk of idiopathic pulmonary fibrosis.

Authors:  Soo-Taek Uh; An-Soo Jang; Sung-Woo Park; Jong-Sook Park; Chang-Gi Min; Yong Hoon Kim; Byung-Lae Park; Hyoung Doo Shin; Dong Soon Kim; Choon-Sik Park
Journal:  Lung       Date:  2014-04-13       Impact factor: 2.584

7.  IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice.

Authors:  Dong Li; Rodrigo Guabiraba; Anne-Gaëlle Besnard; Mousa Komai-Koma; Majid S Jabir; Li Zhang; Gerard J Graham; Mariola Kurowska-Stolarska; Foo Y Liew; Charles McSharry; Damo Xu
Journal:  J Allergy Clin Immunol       Date:  2014-06-27       Impact factor: 10.793

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.